Fred Aslan, Chief Executive Officer at Artiva Biotherapeutics, sold ARTV on Sep 8, 2026
Data as of Oct 16
▼ SELL$256K23,429 shares at $10.92Fred Aslan Chief Executive OfficerARTV Artiva Biotherapeutics, Inc.
- Traded
- Sep 8, 2026
- Disclosed
- Sep 9, 2026
- Filed
- 1 day after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
ARTV since disclosure
−45.8%
after the sale
Similar stocks (XLV) since disclosure
+6.1%
XLV — its sector index fund
Change in closing price from Sep 9, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.